ALLISON INSTITUTE
LIVE

Serial Number

97975242

Owner

The Board of Regents of The University of Texas System

Attorney

Robin Lightner Maisashvili

First Use Date

Nov 14, 2023

Filing Date

Mar 25, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ALLISON INSTITUTE Trademark

Serial Number: 97975242 • Registration: 7845095

ALLISON INSTITUTE is a trademark filed by The Board of Regents of The University of Texas System on March 25, 2022. The trademark is classified under Class 36 (Insurance & Financial), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

The Board of Regents of The University of Texas System (259 trademarks)

201 West 7th Street
Austin, TX 78701

Entity Type: 14

Trademark Details

Filing Date

March 25, 2022

Registration Date

June 24, 2025

First Use Anywhere

November 14, 2023

First Use in Commerce

November 14, 2023

Published for Opposition

February 21, 2023

Goods & Services

Charitable fundraising services

Promoting collaboration within the scientific, research, pharmaceutical, and medical communities to achieve advances in healthcare, including to accelerate the development and use of immunotherapy in treatment of disease

Medical services; Medical services relating to cancer; providing medical information; providing health information in the field of immunobiology, immunotherapy, oncology and diseases; providing a web site featuring medical information; providing a web site featuring health information in the field of immunobiology, immunotherapy, oncology and diseases; providing medical information, consultancy and advisory services; providing information on cancer treatment; providing medical information to patients and medical professionals in the field of immunotherapy and cancer treatment

Medical research services; medical research, development, technical design, testing, and analysis services in the field of immunobiology, immunotherapy, antibodies, and oncology; consulting services in the field of immunobiology, immunotherapy, antibodies, and oncology; medical research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; medical research services in the field of immune repertoire analysis and the genome; scientific research in the fields of immunobiology, immunotherapy, antibodies and oncology; biological research; laboratory research services in the fields of immunobiology, immunotherapy, antibodies, oncology, and cellular engineering; medical laboratory services; providing information on medical and scientific research in the field of immunobiology and immunotherapy; medical and scientific research for others in the field of stem cell research, cancer, immunobiology and immunotherapy; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, immunobiology, immunotherapy, pharmacology and biotechnology; collection and management of medical and scientific data for research purposes in the field of medical and scientific research; Pharmaceutical research services; Pharmaceutical research services relating to cancer

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Jun 24, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Jun 24, 2025 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Jun 2, 2025 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Jun 2, 2025 CNPR
STATEMENT OF USE PROCESSING COMPLETE
May 9, 2025 SUPC
USE AMENDMENT FILED
May 5, 2025 IUAF
TEAS STATEMENT OF USE RECEIVED
May 5, 2025 EISU
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 23, 2025 EXRA
SOU EXTENSION 4 GRANTED
Apr 23, 2025 EX4G
SOU EXTENSION 4 FILED
Apr 16, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
Apr 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 17, 2024 EXRA
SOU EXTENSION 3 GRANTED
Oct 17, 2024 EX3G
SOU EXTENSION 3 FILED
Oct 17, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Oct 17, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 12, 2024 EXRA
SOU EXTENSION 2 GRANTED
Apr 11, 2024 EX2G
SOU EXTENSION 2 FILED
Apr 11, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
Apr 11, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 13, 2023 EXRA
SOU EXTENSION 1 GRANTED
Oct 11, 2023 EX1G
SOU EXTENSION 1 FILED
Oct 11, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 11, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 18, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Feb 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Feb 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 17, 2023 CNSA
EXAMINER'S AMENDMENT ENTERED
Jan 11, 2023 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jan 11, 2023 GNEN
EXAMINERS AMENDMENT E-MAILED
Jan 11, 2023 GNEA
EXAMINERS AMENDMENT -WRITTEN
Jan 11, 2023 CNEA
DIVISIONAL PROCESSING COMPLETE
Dec 12, 2022 DPCC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 5, 2022 AITU
DIVISIONAL REQUEST RECEIVED
Nov 1, 2022 DRRR
TEAS REQUEST TO DIVIDE RECEIVED
Nov 1, 2022 ERTD
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Aug 29, 2022 GNRN
NON-FINAL ACTION E-MAILED
Aug 29, 2022 GNRT
NON-FINAL ACTION WRITTEN
Aug 29, 2022 CNRT
ASSIGNED TO EXAMINER
Aug 25, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 30, 2022 NWOS
NEW APPLICATION ENTERED
Mar 29, 2022 NWAP